Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment

(2010) S. Kumar Pal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate

(2010) Navin Anthony et al.   LEUKEMIA RESEARCH

“Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia

(2010) Roberto Latagliata et al.   LEUKEMIA RESEARCH

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology of chronic myeloid leukaemia (CML)

(2009) Maren Rohrbacher et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

(2009) F. Castagnetti et al.   BLOOD

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

(2009) N. Testoni et al.   BLOOD

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

(2009) G. Rosti et al.   BLOOD

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

(2009) Michele Baccarani et al.   BLOOD

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

(2008) D. Marin et al.   BLOOD

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome

(2008) F. Palandri et al.   HAEMATOLOGICA

Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients

(2008) O. M. Sheehy et al.   Hematology

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

(2008) M Rohrbacher et al.   LEUKEMIA